Chen Lichtenstein - 05 Jun 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Director
Signature: /s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein
Issuer symbol: TEVA
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 16:07:24 UTC
Previous filing: 04 Dec 2024
Next filing: 04 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lichtenstein Chen	Director	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein	09 Jun 2025	0002046465

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+14,492		$0.000000	14,492	05 Jun 2025	Ordinary Shares	14,492		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.